MarksHH.Longevity and mortality of diabetics. Am J Public Health Nations Health, 1965; 55:416–423.
2.
HartmanI.Insulin analogs: Impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res, 2008; 6(2):54–67.
3.
WalterHM, TimmlerR, MehnertH. Stabilized human insulin prevents catheter occlusion during continuous subcutaneous insulin infusion. Diabetes Res, 1990; 13(2):75–77.
4.
NathanDM, GenuthS, LachinJ, et al.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329(14):977–986.
5.
RawshaniA, RawshaniA, FranzénS, et al.Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med, 2017; 376(15):1407–1418.
6.
RawshaniA, SattarN, FranzénS, et al.Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: A nationwide, register-based cohort study. Lancet, 2018; 392:477–486.
7.
AlsalehFM, SmithFJ, KeadyS, et al.Insulin pumps: From inception to the present and toward the future. J Clin Pharm Ther, 2010; 35(2):127–138.
8.
FogtEJ, DoddLM, JenningEM, et al.Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system (Biostator). Clin Chem, 1978; 24(8):1366–1372.
9.
KesavadevJ, SabooB, KrishnaMB, et al.Evolution of insulin delivery devices: From syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther, 2020; 11(6):1251–1269.
10.
WeaverKW, HirschIB. The hybrid closed-loop system: Evolution and practical applications. Diabetes Technol Ther, 2018; 20(S2):S216–S223.
11.
AllenN, GuptaA. Current diabetes technology: Striving for the artificial pancreas. Diagnostics (Basel), 2019; 9(1):31.
12.
Tandem DiabetesCare, Inc. Tandem Diabetes Care, Launches t:slim, Insulin Delivery System. Tandem Diabetes Care, Inc.; 2012.
13.
SchaefferNE.Human factors research applied: The development of a personal touch screen insulin pump and users' perceptions of actual use. Diabetes Technol Ther, 2013; 15(10):845–854.
14.
ZisserHC.The OmniPod Insulin Management System: The latest innovation in insulin pump therapy. Diabetes Ther, 2010; 1(1):10–24.
Johnson & Johnson Diabetes Care Companies. Animas Corporation to Close Operations and Exit Insulin Pump Market. Johnson & Johnson Diabetes Care Companies; 2017.
17.
HoskinsM. NEWS: RocheH and s Over RemainingU.S. Insulin Pump Customers toMedtronic. 2018. Available from: https://www.healthline.com/diabetesmine/roche-hands-off-remaining-pump-customers-medtronic#2 [Last accessed: 2022].
18.
Kaleido. Available from: https://www.hellokaleido.com [Last accessed: 2022].
19.
SOOIL DevelopmentCo., Ltd. History. 2022. Available from: https://sooil.com/about/history.php [Last accessed: October10, 2023].
20.
Eli Lilly and Company. Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes. 2020. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-and-ypsomed-collaborate-advance-automated-insulin-delivery [Last accessed: 2022].
AlmurashiAM, RodriguezE, GargSK. Emerging diabetes technologies: Continuous glucose monitors/artificial pancreases. J Indian Institute Sci, 2023:1–26; doi: 10.1007/s41745-022-0348-3.
23.
GargSK, KipnesM, CastorinoK, et al.Accuracy and safety of Dexcom G7 continuous glucose monitoring in adults with diabetes. Diabetes Technol Ther, 2022; 24(6):373–380.
24.
GargS, LiljenquistDJ, BodeB, et al.Evaluation of accuracy and safety of the next-generation up to 180-day long-term implantable Eversense CGM system: The PROMISE study. Diabetes Technol Ther, 2022; 24(2)84–92.
25.
MastrototaroJ, ShinJ, MarcusA, et al.The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther, 2008; 10:385–390.
26.
AgrawalP, WelshJB, KannardB, et al.Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol, 2011; 5(5):1137–1141.
27.
The Medical Letter on Drugs and Therapeutics. MiniMed 530G: An insulin pump with low-glucose suspend automation. JAMA, 2015; 313(15):1568.
28.
GargS, BrazgRL, BaileyTS, et al.Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: The in-clinic ASPIRE study. Diabetes Technol Ther, 2012; 14(3):205–209.
29.
BergenstalRM, KlonoffDC, GargSK, et al.Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med, 2013; 369(3):224–232.
30.
ZhongA, ChoudharyP, McMahonC, et al.Effectiveness of automated insulin management features of the MiniMed 640G Sensor-augmented insulin pump. Diabetes Technol Ther, 2016; 18(10):657–663.
31.
BuckinghamBA, BaileyTS, ChristiansenM, et al.Evaluation of a predictive low-glucose management system in-clinic. Diabetes Technol Ther, 2017; 19(5):288–292.
32.
SaundersA, MesserLH, ForlenzaGP. MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: Overview of its safety and efficacy. Expert Rev Med Devices, 2019; 16(10):845–853.
33.
BergenstalRM, GargS, WeinzimerSA, et al.Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316(13):1407–1408.
34.
GargSK, WeinzimerSA, TamborlaneWV, et al.Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19(3):155–163.
35.
MesserLH, BergetC, ForlenzaGP. A clinical guide to advanced diabetes devices and closed-loop systems using the CARES Paradigm. Diabetes Technol Ther, 2019; 21(8):462–469.
36.
NimriR, GrosmanB, RoyA, et al.Feasibility study of a hybrid closed-loop system with automated insulin correction boluses. Diabetes Technol Ther, 2021; 23(4):268–276.
37.
CarlsonAL, SherrJL, ShulmanDI, et al.Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24(3):178–189.
38.
BergenstalRM, NimriR, BeckRW, et al.A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): A multicentre, randomised, crossover trial. Lancet, 2021; 397(10270):208–219.
39.
SilvaJD, LeporeG, BattelinoT, et al.Real-world performance of the MiniMed™ 780G System: First report of outcomes from 4120 users. Diabetes Technol Ther, 2022; 24(2):113–119.
40.
CollynsOJ, MeierRA, BettsZL, et al.Improved glycemic outcomes with medtronic MiniMed advanced hybrid closed-loop delivery: Results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care, 2021; 44(4):969–975.
41.
MesserLH, CampbellK, PyleL, et al.Basal-IQ technology in the real world: Satisfaction and reduction of diabetes burden in individuals with type 1 diabetes. Diabet Med, 2021; 38(6):e14381.
42.
PinskerJE, MüllerL, ConstantinA, et al.Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology. Diabetes Technol Ther, 2021; 23(2):120–127.
43.
ForlenzaGP, LiZ, BuckinghamBA, et al.Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG Trial. Diabetes Care, 2018; 41(10):2155–2161.
44.
BretonMD, KovatchevBP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther, 2021; 23(9):601–608.
45.
BrownSA, KovatchevBP, RaghinaruD, et al.Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381(18):1707–1717.
46.
ForlenzaGP, EkhlaspourL, BretonM, et al.Successful at-home use of the tandem control-IQ artificial pancreas system in young children during a randomized controlled trial. Diabetes Technol Ther, 2019; 21(4):159–169.
47.
BrownSA, ForlenzaGP, BodeBW, et al.Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care, 2021; 44(7):1630–1640.
48.
ForlenzaGP, BuckinghamBA, ChristiansenMP, et al.Performance of OmniPod personalized model predictive control algorithm with moderate intensity exercise in adults with type 1 diabetes. Diabetes Technol Ther, 2019; 21(5):265–272.
49.
SherrJL, BodeBW, ForlenzaGP, et al.Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: A single-arm multicenter clinical trial. Diabetes Care, 2022; 45(8):1907–1910.
50.
JDRF. FDA Authorizes OmniPod 5 for Ages 2+ in Children with Type 1 Diabetes. 2022. Available from: https://www.jdrf.org/blog/2022/08/22/fda-authorizes-omnipod-5-ages-2-children-with-type-1-diabetes/
51.
AmadouC, FrancS, BenhamouPY, et al.Diabeloop DBLG1 closed-loop system enables patients with type 1 diabetes to significantly improve their glycemic control in real-life situations without serious adverse events: 6-Month follow-up. Diabetes Care, 2021; 44(3):844–846.
52.
ThabitH, TauschmannM, AllenJM, et al.Home use of an artificial beta cell in type 1 diabetes. N Engl J Med, 2015; 373(22):2129–2140.
53.
TauschmannM, ThabitH, BallyL, et al.Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial. Lancet, 2018; 392(10155):1321–1329.
54.
GargSK, PolskyS. Technology use and glycemic outcomes during pregnancy with type 1 diabetes. NEJM, 2023; doi: 10.1056/NRJMe2310798
55.
LeeTTM, CollettC, BergfordS, et al.Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med, 2023; doi: 10.1056/NEJMoa2303911.
56.
LewisDM.Do-it-yourself artificial pancreas system and the OpenAPS Movement. Endocrinol Metab Clin North Am, 2020; 49(1):203–213.
57.
KesavadevJ, SrinivasanS, SabooB, et al.The do-it-yourself artificial pancreas: A comprehensive review. Diabetes Ther, 2020; 11(6):1217–1235.
58.
OliverN, ReddyM, MarriottC, et al.Open source automated insulin delivery: Addressing the challenge. NPJ Digit Med, 2019; 2:124.
59.
LewisDM, HussainS. Practical guidance on open source and commercial automated insulin delivery systems: A guide for healthcare professionals supporting people with insulin-requiring diabetes. Diabetes Ther, 2022; 13(9):1683–1699.
60.
CrabtreeTSJ, ChoudharyP, LumbA, et al.Association of British clinical diabetologists, diabetes technology network UK and association of children's diabetes clinicians survey of UK healthcare professional attitudes towards open-source automated insulin delivery systems. Diabetes Ther, 2022; 13(2):341–353.
61.
RussellSJ, BeckRW, DamianoER, et al.Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med, 2022; 387(13):1161–1172.
62.
BeckRW, RussellSJ, DamianoER, et al.A multicenter randomized trial evaluating fast-acting insulin aspart in the bionic pancreas in adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24:681–696.
63.
KrugerD, KassA, LonieJ, et al.A multienter randomied trial evaluating the insulin-only configuration of the bionic pancrease in adults with type 1 diabets. Diabetes Technol Ther, 2022; 24:697–711.
64.
MesserLH, BuckinghamBA, CogenF, et al.Positive impact of the bionic pancreas on diabetes control in youth 6–17 years old with type 1 diabetes: A multicenter randomized trial. Diabetes Technol Ther, 2022; 24:712–725.
65.
LynchJ, KanapkaLG, RussellSJ, et al.The insulin-only bionic pancrease pivotal trial extension study: A multi-center single-arm evaluation of the insulin-only configuration of the bionic pancreas in adults and youth with type 1 diabetes. Diabetes Technol Ther, 2022; 24:726–736.
66.
GargSK, HenryRR, BanksP, et al.Effects of sotagliflozin added to insulin in type 1 diabetes. N Engl J Med, 2017; 377(24):2337–2348.
VigerskyRA, ShinJ.The myth of MARD: Limitations of MARD in the clinical assessment of continuous glucose monitoring data. Diabetes Technol Ther, 2024; 26(Suppl. 3).
69.
GrosmanB, AnirbanR, LintereurL, et al.A peek under the hood: Explaining the MiniMed 780G algorithm with meal detection technology. Diabetes Technol Ther, 2024; 26(Suppl. 3).
70.
SherrJ, ConsidineE.Real-world evidence of automated insulin delivery system use. Diabetes Technol Ther, 2024; 26(Suppl. 3).
71.
ThasherJR, ArrietaA, NiuF, et al.Early real-world performance of the MiniMed 780G advanced hybrid closed-loop system and recommended settings use in the United States. Diabetes Technol Ther, 2024; 26(Suppl. 3).
O'NealDN, ZaharievaDP, MorrisonD, et al.Exercising safely with the MiniMed 780G automated insulin delivery system. Diabetes Technol Ther, 2024; 26(Suppl. 3).
74.
PetrovskiG, CampbellJ, PashaM, et al.12-month follow-up from a randomized controlled trial of simplified meal announcement versus precise carbohydrate counting on adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed loop system. Diabetes Technol Ther, 2024; 26(Suppl. 3).
75.
ChoudharyP, van den HeuvelT, ArrietaA, et al.Celebrating the data from 100,000 real world users of the MiniMed 780G system in Europe, Middle East, and Africa collected over 3 years—From data to clinical evidence. Diabetes Technol Ther, 2024; 26(Suppl. 3).
76.
MatheiuC, AhmedWS, GillardP, et al.The health economics of automated insulin delivery systems and the use of time in range in diabetes modeling: A narrative review. Diabetes Technol Ther, 2024; 26(Suppl. 3).
